Close

Tjoapack invests in automated injectables packaging capabilities

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Oncology start-ups urged to apply and accelerate their business with Discovery Spark

Applications open for Discovery Park’s oncology themed ‘Discovery...

2025 AI Trends & Pharma Predictions

As we navigate what the future of healthcare will...

Swiss Airtainer reaches major milestone with successful completion of first 50 commercial shipments

Swiss Airtainer is pleased to announce the successful completion of its first 50 commercial shipments of high-value life science...

Tjoapack is investing in its automated packaging capabilities to meet growing customer demand for pre-filled syringes and vials.

The automated packaging line for vials will start operations in Q1 2021 and will increase its capacity to over 12 million vials per year. Its pre-filled syringes (PFS) capabilities are expected to be operational by Q4 of 2021.

The automated PFS packaging line will have an initial capacity for 7 million syringes per year and will assemble, automate insertion of plunger rods and back-stops, carry out inline labelling and complete coding and vision control.

The investment follows increased demand from existing and new customers for pre-filled and vial packaging in line with the prevalence of chronic diseases that require injectable therapies.

This latest addition to Tjoapack’s service offering follows the recent investment by private equity firm and healthcare specialists, Ampersand Capital Partners.

Dexter Tjoa, CEO at Tjoapack said: “At Tjoapack we’re committed to ensuring we consistently bolster our offering and deliver the efficient and flexible services that our clients expect. The investment from Ampersand allows us to build on our strong foundations, expand our service offering, and ensure we continue to meet customer demand.

Dexter added: “As new therapies emerge to address unmet patient needs for chronic ailments the demand for contract packaging organisation that can handle syringes and vials will continue to rise.

Technological advancements, improving patient compliance, beneficial reimbursement policies, and the rise of biologics in the pharmaceutical market will also further propel the needs for service providers who can meet these requirements.”

Founded in 1989, Tjoapack is an independent contract packager of medicines servicing clients across five continents and 42 countries.

The CPO specialises in primary packaging for solid dosage forms, secondary packaging and unit dose packaging and now has a total of 18 packaging lines for blisters, bottles, and vials. Using these lines, it packages around 35 million packs of pharmaceutical products per year.

Latest stories